Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery. Participants from the United States and Canada will be recruited for this study.
Epistemonikos ID: cf91da13e8f976afaf868ed5764815764473d44b
First added on: May 10, 2024